IN2012DN02345A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02345A
IN2012DN02345A IN2345DEN2012A IN2012DN02345A IN 2012DN02345 A IN2012DN02345 A IN 2012DN02345A IN 2345DEN2012 A IN2345DEN2012 A IN 2345DEN2012A IN 2012DN02345 A IN2012DN02345 A IN 2012DN02345A
Authority
IN
India
Prior art keywords
nucleic acid
stranded
methods
tlrs
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Bruce A Sullenger
Jaewoo Lee
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of IN2012DN02345A publication Critical patent/IN2012DN02345A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN2345DEN2012 2009-09-16 2010-09-16 IN2012DN02345A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24309009P 2009-09-16 2009-09-16
PCT/US2010/002516 WO2011034583A2 (en) 2009-09-16 2010-09-16 Inhibition of endosomal toll-like receptor activation

Publications (1)

Publication Number Publication Date
IN2012DN02345A true IN2012DN02345A (enExample) 2015-08-21

Family

ID=43759220

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2345DEN2012 IN2012DN02345A (enExample) 2009-09-16 2010-09-16

Country Status (6)

Country Link
US (3) US9468650B2 (enExample)
EP (1) EP2477641B1 (enExample)
CN (1) CN102639142A (enExample)
CA (1) CA2774460C (enExample)
IN (1) IN2012DN02345A (enExample)
WO (1) WO2011034583A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008121354A1 (en) 2007-03-30 2008-10-09 Duke University A method of modulating the activity of a nucleic acid molecule
IN2012DN02345A (enExample) 2009-09-16 2015-08-21 Univ Duke
WO2012151575A2 (en) 2011-05-05 2012-11-08 Duke University A method of controlling coagulation
WO2014169043A1 (en) * 2013-04-09 2014-10-16 Duke University Anti-inflammatory agents and methods of using the same
US10066323B2 (en) 2014-04-16 2018-09-04 Duke University Electrospun cationic nanofibers and methods of making and using the same
JP7560821B2 (ja) 2016-09-16 2024-10-03 デューク ユニバーシティ フォン・ビルブラント因子（ｖｗｆ）標的薬剤およびそれを用いる方法
WO2018119422A1 (en) 2016-12-22 2018-06-28 Duke University Polycationic microfibers and methods of using the same
US11634772B2 (en) 2017-03-23 2023-04-25 Duke University Antidote-mediated reversal of extracellular aptamer staining
WO2018222484A1 (en) * 2017-05-30 2018-12-06 The Trustees Of Columbia University In The City Of New York Cationic nucleic acid scavenger and uses thereof
WO2019051397A1 (en) 2017-09-08 2019-03-14 Duke University NUCLEOLIN TARGETING APTAMERS AND METHODS OF USE
WO2021016924A1 (zh) * 2019-07-31 2021-02-04 中山大学 可用于治疗银屑病的阳离子聚合物及颗粒
EP4249913A1 (en) * 2022-03-22 2023-09-27 Centre Hospitalier Universitaire de Nîmes Toll-like-receptor 3 inhibitor for preventing and/or treating disorders in patients with a personal history of venous thromboembolism (vte)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919761A (en) 1992-08-14 1999-07-06 The Board Of Regents Of The University Of Michigan Peptides for heparin and low molecular weight heparin anticoagulation reversal
US6037329A (en) 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
EP1343371A4 (en) 2000-09-08 2004-08-04 Invitrogen Corp COMPOSITIONS AND METHODS FOR IMPROVED SENSITIVITY AND SPECIFICITY OF NUCLEIC ACID SYNTHESIS
USRE43612E1 (en) 2000-10-10 2012-08-28 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
EP1347776A2 (en) * 2001-01-05 2003-10-01 Intercell Biomedizinische Forschungs- und Entwicklungs AG Anti-inflammatory use of polycationic compounds
JP2004520836A (ja) 2001-03-08 2004-07-15 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 低減された免疫原性を有する修飾されたプロタミン
EP1401853B1 (en) 2001-05-25 2010-09-22 Duke University Modulators of pharmacological agents
AUPR604101A0 (en) 2001-06-29 2001-07-26 Unisearch Limited Aptamers
US20050136040A1 (en) * 2001-10-11 2005-06-23 Imperial College Innovations Limited Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
US20030157030A1 (en) 2001-11-02 2003-08-21 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
US20030180250A1 (en) * 2002-03-22 2003-09-25 Council Of Scientific And Industrial Research Compositions and complexes containing a macromolecular compound as potential anti-inflammatory agents
KR20050051686A (ko) 2002-10-09 2005-06-01 인설트 테라페틱스, 인코퍼레이티드 사이클로덱스트린-기초한 재료, 조성물 및 이의 용도
US20050256071A1 (en) 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
AU2004320900A1 (en) 2003-07-15 2006-02-23 California Institute Of Technology Improved inhibitor nucleic acids
DK1745062T3 (da) 2004-04-22 2014-08-11 Regado Biosciences Inc Forbedrede modulatorer af koagulationsfaktorer
WO2007001332A2 (en) * 2004-08-04 2007-01-04 University Of Massachusetts Anti-pathogen immunoadhesins
GB0422877D0 (en) 2004-10-14 2004-11-17 Univ Glasgow Bioactive polymers
CA2603730A1 (en) 2005-03-31 2006-10-05 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
US7611835B2 (en) 2005-09-30 2009-11-03 Battelle Memorial Institute Process for preparing multilayer enzyme coating on a fiber
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
AU2007267801A1 (en) 2006-05-26 2007-12-06 Regado Biosciences, Inc. Administration of the REG1 anticoagulation system
CN101528263B (zh) * 2006-06-30 2013-01-23 Sku资产管理有限公司 用于癌症的先天性免疫方法的缀合物
WO2008066621A2 (en) 2006-10-19 2008-06-05 Duke University Reversible platelet inhibition
WO2008063157A2 (en) 2006-10-25 2008-05-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A nanoparticle-based anticoagulant
EP2129389B1 (en) 2007-02-15 2014-10-08 MannKind Corporation A method for enhancing t cell response
WO2008121354A1 (en) * 2007-03-30 2008-10-09 Duke University A method of modulating the activity of a nucleic acid molecule
KR20100082840A (ko) 2007-09-27 2010-07-20 에스체아 히기에너 프로덕츠 악티에볼라그 클레이결합된 폴리머 겔
US20100285081A1 (en) 2007-11-12 2010-11-11 Massachusetts Institute Of Technology Bactericidal Nanofibers, and Methods of Use Thereof
WO2010020008A1 (en) 2008-08-22 2010-02-25 Polymers Crc Limited Polymer coatings
WO2010132879A2 (en) 2009-05-15 2010-11-18 The Johns Hopkins University Multicomponent degradable cationic polymers
IN2012DN02345A (enExample) 2009-09-16 2015-08-21 Univ Duke
WO2012088059A2 (en) 2010-12-20 2012-06-28 Virginia Commonwealth University A facile method for crosslinking and incorporating bioactive molecules into electrospun fiber scaffolds
US20140234373A1 (en) 2011-09-16 2014-08-21 Georfia Regents University Methods of Promoting Immune Tolerance

Also Published As

Publication number Publication date
US9468650B2 (en) 2016-10-18
US11617779B2 (en) 2023-04-04
US20120183564A1 (en) 2012-07-19
CN102639142A (zh) 2012-08-15
US20170095503A1 (en) 2017-04-06
EP2477641A2 (en) 2012-07-25
WO2011034583A3 (en) 2011-10-06
EP2477641B1 (en) 2024-03-27
WO2011034583A2 (en) 2011-03-24
EP2477641A4 (en) 2013-08-07
US20230248805A1 (en) 2023-08-10
CA2774460C (en) 2016-08-09
CA2774460A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
IN2012DN02345A (enExample)
EP2569453A4 (en) Nucleic Acid ISOLATION METHOD
WO2020198509A3 (en) Modified oligonucleotides with increased stability
BR112014005205A2 (pt) métodos para etiquetar bibliotecas codificadas com dna
WO2007136736A3 (en) Methods for nucleic acid sorting and synthesis
MX2010002113A (es) Metodos para detectar oligonucleotidos.
IL190501A0 (en) Multicomponent nucleic acid enzymes and methods for their use
BR112014007852A2 (pt) nucleosídeos, nucleotídeos e ácidos nucleicos modificados e usos dos mesmos
IN2014DN03463A (enExample)
WO2008063203A3 (en) Compositions and methods for efficient gene silencing in plants
WO2008061537A3 (en) Oligonucleotides for modulating target rna activity
SG170802A1 (en) Systems and devices for sequence by synthesis analysis
WO2009012363A3 (en) Nucleotides and aptamers containing boronic acid groups having biased binding to glycosylated proteins, and uses thereof
WO2008151631A8 (en) Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
EP3358014A3 (en) Method for stabilizing functional nucleic acids
WO2005097993A3 (en) Immunostimulatory viral rna oligonucleotides
WO2006019430A3 (en) Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells
EP2647711A3 (en) Alternative export pathways for vector expressed RNA interference
AR067135A1 (es) Metodos para aislar arn de fragmento largo de muestras fijas
WO2008092081A8 (en) Targeted delivery of sirna
EE200200051A (et) Tenastsiin C nukleiinhappelised ligandid
WO2011056073A3 (en) Novel compounds for modulating neovascularisation and methods of treatment using these compounds
BR112014021993A2 (pt) detecção da variação de nucleotídeo em sequência de ácido nucleico alvo através de ensaio de clivagem e extensão de pto
MX362061B (es) Ácidos nucleicos de enlace c5a nuevos.
MX2014008104A (es) Aptameros y metodos de diagnostico para detectar el receptor de egf.